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Abstract The frequency and function of regulatory T
cells (Tregs) were studied in stage II–III melanoma patients
who were enrolled in a phase II randomized trial of vac-
cination with HLA-A*0201-modified tumor peptides ver-
sus observation. The vaccinated patients received low-dose
cyclophosphamide (CTX) and low-dose interleukin-2 (IL-
2). Tregs were analyzed in the lymph nodes (LNs) of stage
III patients who were undergoing complete lymph node
dissection and in peripheral blood mononuclear cells
(PBMCs) collected before vaccination and at different time
points during the vaccination period. The LNs of the vac-
cinated patients, which were surgically removed after two
rounds of vaccination and one dose of CTX, displayed a
low frequency of Tregs and a less immunosuppressive
environment compared with those of the untreated patients.
The accurate time-course analysis of the PBMCs of
patients enrolled in the vaccination arm indicated a limited
and transient modulation in the frequencies of Tregs in
PBMCs collected after low-dose CTX administration and a
strong Treg boost in those PBMCs collected after low-dose
IL-2 administration. However, a fraction of the IL-2-
boosted Tregs was functionally modulated to a Th-1-like
phenotype in the vaccinated patients. Moreover, low-dose
IL-2 promoted the concomitant expansion of conventional
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activated CD4? T cells. Despite the amplification of Tregs,
IL-2 administration maintained or further increased the
number of antigen-specific CD8? T cells that were induced
by vaccination as demonstrated by the ex vivo human
leukocyte antigen-multimer staining and IFN-c ELISpot
assays. Our study suggests that the use of CTX as a Treg
modulator should be revised in terms of the administration
schedule and of patients who may benefit from this drug
treatment. Despite the Treg expansion that was observed in
this study, low-dose IL-2 is not detrimental to the func-
tional activities of vaccine-primed CD8? T cell effectors
when used in the inflammatory environment of vaccination.
Keywords Regulatory T cells  Cyclophosphamide 
Melanoma  Immunotherapy
Introduction
Regulatory T cells (Tregs) are essential for the maintenance
of self-tolerance and immune homeostasis, and their arche-
typal feature is the ability to suppress the activation, prolif-
eration, and effector functions of a wide variety of immune
cells, mostly in a contact-dependent manner [1]. The rele-
vance of CD4? Tregs in suppressing the anti-tumor immune
response is well documented, and numerous studies have
reported that the accumulation of Tregs in cancer patients is
generally associated with tumor progression, a poor prog-
nosis and the suppression of anti-tumor immunity [2, 3]. The
influence of Tregs in down-modulating anti-tumor immunity
is an area of intense investigation, and several strategies have
been employed to either block or eliminate Tregs [4–6]. In
murine models, cyclophosphamide [N,N-bis (2-chloroethyl)-
1, 3, 2-oxazaphosphinan-2 amine 2-oxide, the generic name
for Cytoxan (CTX) or Endoxan] acts by limiting the number
of circulating Tregs [7, 8]. In human settings, the biological
activities of CTX are dose-dependent, and metronomic dos-
ing has been demonstrated to limit Treg expansion in patients
with advanced cancer [9–11]. However, there is no consensus
on the immunological properties of low-dose CTX, most
likely because of the different treatment schedules that have
been applied and the heterogeneous methods that have been
used to detect Tregs [12–15].
Naturally occurring activated Tregs, ready to exert their
suppressive activities, are defined as CD4?CD25hiFoxp3?
T cells [16]. The definition of Tregs using multiparametric
FACS analysis according to the CD4/CD25/Foxp3 pheno-
type allows additional functional markers to be combined
and the direct ex vivo profiling of these cells, which is
crucial because of the functional heterogeneity and the high
lineage plasticity of Tregs [1, 17, 18].
CD25 is the a-chain of the IL-2 receptor, which is con-
stitutively expressed by Tregs; therefore, Tregs are highly
responsive to IL-2 and IL-2 receptor triggering delivers
essential signals for Treg development, homeostasis and
function [19]. The in vivo administration of high-dose IL-2 to
cancer patients or patients with immune-mediated disease
leads to a strong expansion of circulating Tregs [20, 21].
In this study, we extensively monitored the behavior of
Tregs in early-stage melanoma patients who received low-
dose CTX and low-dose IL-2 in a phase II randomized trial.
Tregs in peripheral blood and in LNs were investigated
with a combination of phenotypic and functional markers
to understand the plasticity of these cells in the context of
tumor-specific immunization. Immune monitoring of vac-
cine-induced T cell responses was performed to determine
the outcomes of Treg modulation in the patient immune
responses to the vaccine.
Materials and methods
Study design and patient eligibility criteria
A phase II randomized study of HLA-A*0201-positive
patients with stage IIB/C–III melanoma was conducted.
The study included vaccination and observation arms.
The peptides that were used in this study were synthesized
under GMP conditions by Merck Biosciences AG, Clinalfa
(La¨ufelingen, Switzerland) ([95 % purity). The vaccine
included the following four modified peptides (Altered
Peptide Ligands, APL): HLA-A*0201-restricted (Melan-A/
MART-1[27L], gp100[210M], NY-ESO-1[165V], and Sur-
vivin[97M]). For each peptide, 250 lg was emulsified in
0.5 ml Montanide-ISA51 (Seppic, Franklin Lakes, NJ, USA)
and injected subcutaneously (s.c.). The first two vaccines
were injected in the proximity of the LNs to be dissected by
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surgery: (1) inguinal LNs: in the upper part of the thigh,
approximately 5–6 cm from the inguinal ligament and (2)
axillary LNs: in the center of the deltoid area. The other
vaccinations were injected close to the inguinal and axillary
lymph node regions, the different LN stations were rotated,
and the dissected station was excluded. In addition, the
patients in the vaccination arm received CTX (Endoxan)
(300 mg/m2 i.v.) and IL-2 (Proleukin) (3 9 106 IU, s.c.).
The vaccination schedule and the drug administration
schedule are detailed in Online figure 1.
Patients were selected after primary tumor removal and
enrolled at the Fondazione IRCCS Istituto Nazionale dei
Tumori of Milan, Azienda Ospedaliera Universitaria Se-
nese of Siena and Istituto Oncologico Veneto of Padua.
The protocol was conducted in compliance with the Dec-
laration of Helsinki and was approved by the ethics com-
mittees of each institution. Written informed consent was
obtained from each subject. Patients with histologically
confirmed (American Joint Committee on Cancer) stage
IIB/C–III resectable melanoma (ECOG score 0–1) and
normal hematopoietic, liver and renal function were eligi-
ble. Of the 43 patients who were enrolled, 22 were ran-
domized into the vaccination arm and 21 into the
observation arm. Samples from 16 patients in each group
were available for the Treg analysis after blood collection.
Patients in the observation arm received neither vaccina-
tion nor IL-2 and CTX. The PBMCs of stage IV melanoma
patients who were admitted to the Fondazione IRCCS Is-
tituto Nazionale dei Tumori of Milan and who were not
eligible for this vaccination study were collected after
informed consent was obtained. The PBMCs were used to
determine the baseline frequency of the circulating Tregs,
which is reported in Online figure 3.
Blood and tissue samples
Blood samples were collected from healthy donors and
patients. PBMCs were isolated using Ficoll-PaqueTM PLUS
density gradient centrifugation as previously described [22].
Patients with tumor-positive sentinel nodes underwent
complete lymph node dissection (CLND). The LN material,
which was left over by the pathologist after the diagnostic
procedures, was immediately processed (within an hour)
into a single-cell suspension. Using enzymatic digestion or
mechanical dissociation, cell suspensions were obtained
from each single LN with a known tumor invasion status
based on the pathological assessment, and the suspensions
were analyzed as separate samples. For patients with tumor-
positive nodes among the lymph nodes that were obtained
by CLND, both tumor-involved and tumor-free LNs were
examined when available.
The sera were prepared by clotting the blood samples
with a clot activator and a separating gel (BD Biosciences,
San Jose`, CA). After incubation at RT for 30 min, the
serum was obtained by centrifugation at 1,8009g for
10 min and subsequently stored at -80 C until use.
T cell analysis
FACS analysis was performed using thawed PBMCs and
LN-derived lymphocytes with the following mAbs:
APCH7 or APC-conjugated anti-CD4, PE-Cy7-conjugated
anti-CD25, FITC-conjugated anti-CD45RA and fluoro-
chrome-conjugated mouse IgG as an isotype control (all of
the antibodies were purchased from BD Biosciences).
Intracellular staining with PE- or APC-conjugated rat
IGg2a Kappa anti-Foxp3 mAbs (eBioscience, San Diego,
CA) was performed according to the manufacturer’s
instructions. For each single patient, Treg staining was
simultaneously performed. In the analysis, activated Tregs
were defined as CD4?Foxp3?CD25hi. The CD25hi region
was set to include 100 % positive Foxp3 cells. For some
experiments, as indicated in the legends of the corre-
sponding figures, an anti-CD45RA mAb was included to
allow for the analysis of conventional activated T cells that
were gated as CD4?CD25intFoxp3intCD45RAneg.
For the intracellular staining of lymphocytes, PBMCs
were freshly isolated or activated overnight with anti-CD3/
CD28 beads (DynaBeads CD3/CD28 T cell Expander,
Invitrogen Dynal AS, Oslo, Norway) (the PBMC:beads
ratio was 25:1) in the presence of 1 ll/ml Golgi Plug (BD
Biosciences). The PBMCs were stained for cell surface
markers, fixed and permeabilized with Cytofix/Cytoperm
buffer (BD Biosciences) and stained with PE-labeled anti-
IFN-c or FITC-labeled anti-Ki67 (BD Biosciences), PE-
labeled anti-T-bet (eBioscience) or PE-labeled anti-TGF-b1
(IQ Products, Groningen, The Netherlands). When com-
bined with the anti-Foxp3 antibody, staining was performed
using eBioscience Fixation/Permeabilization buffers.
The distribution of CD25- and Foxp3-positive cells was
similar in unstimulated and in ex vivo activated CD4?
cells. CD4? cells that exhibited the phenotypic traits of
activated Tregs, CD25hiFoxp3hi, and conventional acti-
vated T cells with intermediate expression of CD25 and
Foxp3 and no expression of the CD45RA were both clearly
evident in ex vivo activated PBMCs.
The fluorescence intensity was measured using a Navi-
osTM (Beckman Coulter, Brea, CA) flow cytometer and
analyzed using FlowJo Cytometry Analysis software
(Tree Star Inc., Ashland, OR).
Isolation of Treg
Tregs were purified from PBMCs using immunomagnetic
sorting with the human CD4?CD25? Regulatory T Cell
Isolation Kit according to the manufacturer’s instructions
Cancer Immunol Immunother (2013) 62:897–908 899
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(Miltenyi Biotec, Bergisch Gladbach, Germany). The
purity of the isolated cells ([95 %) was determined using
surface staining with anti-CD4 and anti-CD25 mAbs.
Suppression assay
In vitro suppression assays were performed in 96-well
round-bottom plates and evaluated using a CFSE prolifer-
ation assay as previously described [23]. The proliferation
of responder T cells was evaluated after 72 h.
Bio-Plex assay
Snap-frozen primary tumor samples were mechanically
disrupted and were treated with lysis solution (Bio-Rad
Laboratories, Inc., Hercules, California, USA). After son-
ication, the samples were centrifuged at 4,500g for 10 min
at 4 C. The protein concentrations in the lysates were
determined using the Pierce BCA Protein Assay Kit
(Thermo Scientific) and were adjusted to 250 lg/ml using
a serum diluent (Bio-Rad). The concentrations of the
inflammatory factors in the tissue lysates were measured
using multiplex technology (Bio-Rad).
Cytokine FlowCytomix
The IL-12p70 levels in the patient and healthy donor sera
were measured using the FlowCytomixTM Multiple Ana-
lyte Detection System (eBioscience) according to the
manufacturer’s protocol. The analysis was performed using
a BD FACSCalibur flow cytometer, and the cytokines
were quantified using Pro 2.4 FlowCytomixTM software.
ELISpot
Immunomonitoring was performed using an ex vivo IFN-c
ELISpot assay (1-D1K, Mabtech AB, Nacka, Sweden) after
thawed PBMCs were incubated overnight at 37 C in
culture medium as previously described [23]. The data
were evaluated using the A.EL.VIS ELISpot Reader
(Thema Ricerca, Bologna, IT). The results are presented as
the number of APL-reactive cells/2 9 105 CD8? cells.
Multimer staining
Peptide/HLA-A*0201-multimers were provided by Pro-
immune (Ltd., Oxford, UK) and were used as previously
described [24]. The fluorescence intensity was evaluated
using a BD FACSCalibur flow cytometer and was ana-
lyzed using FlowJo Cytometry Analysis software (Tree
Star Inc., Ashland, OR). A phycoerythrin-conjugated HLA-
A*0201-negative multimer was used as a control.
Statistics
Student’s t tests and two-tailed Wilcoxon matched pairs
tests (confidence interval [Cl] 95 %) were used as indicated
in the figure legends. The statistical calculations were
performed using Prism5 software (GraphPad Software, La
Jolla, CA, USA). A p value B0.05 was considered statis-
tically significant.
Results
Patient treatment
HLA-A*0201-positive stage IIB/C–III melanoma patients
were enrolled in this phase II study and were randomized
into two different arms: vaccination or observation only.
The patients in the vaccination arm received the following
four modified peptides (Altered Peptide Ligands, APL):
HLA-A*0201-restricted (Melan-A/MART-1[27L], gp100
[210M], NY-ESO-1[165V], and Survivin[97M]). The
patients in the vaccination arm received low-dose CTX
(300 mg/m2 i.v.) as a potential Treg-depleting agent
1 week before vaccination and 7 and 11 weeks following
the initiation of vaccination. To boost the vaccine-induced
immune responses, these patients received three daily
injections of low-dose IL-2 (3 9 106 IU) at a late admin-
istration time period, i.e., at weeks 13 and 15, according to
a strategy that was suggested by Slingluff and collaborators
[25]. In the control arm, the patients received no treatment
other than surgery. The patient characteristics, treatment
schedule, and study design are detailed in the Online
table 1 and in the Online figure 1. The clinical outcomes of
this study are reported elsewhere [26].
Lymph nodes of vaccinated patients displayed a less
immunosuppressive environment
Based on a positive sentinel node biopsy, the stage III
melanoma patients who were enrolled in the study under-
went surgical LN dissection. According to the treatment
schedule, the patients in the vaccination arm received one
dose of the CTX treatment and two rounds of vaccination
before regional LN removal (Online figure 1). The LN
material, which was left over by the pathologist after the
diagnostic procedures, was immediately processed into a
single-cell suspension and assessed by FACS analysis for
the presence of CD4?CD25hiFoxp3?activated Tregs. Cell
suspensions were obtained from each single LN with a
known tumor invasion status according to the pathological
assessment, and the suspensions were analyzed as separate
samples. The LNs of the vaccinated patients (14 LNs, of
which n = 4 had macroscopical metastases) were more
900 Cancer Immunol Immunother (2013) 62:897–908
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homogenous according to their Treg content and displayed
a low Treg frequency compared with those of the patients
who only received surgical treatment (8 LNs, of which
n = 2 had macroscopical metastases) (% of Tregs mean ±
SEM: 2.9 ± 1.1 and 5.6 ± 1.5 in the vaccinated and
control LNs, respectively; p = 0.0274) (Fig. 1a). In addi-
tion, the different Treg distributions in the LNs of the
vaccinated and control patients were confirmed by IHC
(Online table 2).
To determine whether the CTX and vaccination treat-
ments impacted the immunological milieu of the tumor
microenvironment, we investigated the presence of chronic
inflammatory mediators in the lysates that were prepared
from metastatic LNs, which were surgically removed from
the control (n = 3) and vaccinated (n = 5) patients using a
Bio-Plex assay. As shown in Fig. 1b, the majority of the
tested inflammatory factors was detected at significantly
lower levels in the LNs of the treated patients compared
with those of the control patients. Significant reductions in
the IL-10 (p = 0.0148), IL-6 (p = 0.0157), and vascular
endothelial growth factor (VEGF) (p = 0.0015) levels
were evident in the LNs of patients who received CTX and
vaccination, which suggests that an amelioration of the
local immunosuppressive networks occurred. To confirm
these findings, IL-10 and TGF-b1 production by the LN-
resident CD4?CD25? T cells was evaluated ex vivo upon
TCR triggering in 9 additional LNs (5 control LNs, of
which 0 had macroscopical metastasis and 4 vaccination
LNs, of which 2 had macroscopical metastases). Figure 1c
shows that the CD4?CD25? cells, which secreted these
suppressive cytokines, were decreased in the LNs of the
patients who received CTX and vaccination compared with
those of the control patients [% of IL-10 in CD4?CD25?
mean ± SEM: VAX (29.8 ± 12.4) vs. CRL (76.1 ± 1.1);
% of TGF-b1 in CD4?CD25? mean ± SEM: VAX
(23.7 ± 4.6) vs. CRL (49.8 ± 1.9)]. In contrast, similar
levels of GM-CSF were detected both in the LNs of the
treated patients and in those of the control patients, which
suggests that this cytokine was not affected by the CTX/
vaccination treatments and supports the in vivo generation
of MoDCs in tumor-draining LNs during vaccination.
CTX- and IL-2-induced modulation of circulating
Tregs in vaccinated melanoma patients
The frequency of circulating Tregs was monitored in the
peripheral blood of vaccinated and unvaccinated patients
by FACS analysis at different time points.
The PBMCs that were obtained from treated patients
4–7 days after CTX administration (B1, Fig. 2a) displayed
a slight although statistically significant decrease in the
frequency of activated CD4?CD25hiFoxp3? Tregs com-
pared with the pre-treatment samples (B0, Fig. 2a) (% of
Tregs mean ± SEM: B0 (1.7 ± 0.3), B1 (1.3 ± 0.2);
p = 0.0215). However, the reduction in the frequency of
Tregs was transient, and at week 8 (B4, Fig. 2a), the
number of Tregs returned to the initial pre-treatment levels.
As expected, the late administration of low-dose IL-2
(3 9 106 IU s.c. for 3 days at week 13 and 15, see Online
Fig. 1 The LN environment of the vaccinated patients was less
immunosuppressive than that of the control patients. a The lympho-
cytes that were obtained from patient LNs were stained with anti-
CD4, anti-CD25, and anti-Foxp3 mAbs and were assessed by FACS
analysis. A comparison between the Treg frequency (CD25hiFoxp3?
in CD4? cells) in the control patient LNs (CRL, n = 8) and in the
vaccinated patient LNs (VAX, n = 13) was made. b The GM-CSF,
G-CSF, IL-1b, IL-6, VEGF, and IL-10 levels were detected in the
LNs using a Bio-Plex assay and expressed as pg/mg protein (the mean
and the SEM) in the control (CRL, white bars, n = 3) and vaccinated
(VAX, black bars, n = 5) patients. c The lymphocytes from the LNs
of the control (CRL, n = 5) and vaccinated (VAX, n = 4) patients
were activated ex vivo with anti-CD3/CD28 beads and were stained
for the surface expression of CD4 and CD25 and the intracellular
expression of IL-10 and TGF-b1. The graphs show the percentages of
the IL-10-producing cells (left panel) and TGF-b1-producing cells
(right panel) in the CD4?CD25? lymphocytes. The significant
p values were calculated using Student’s t test
Cancer Immunol Immunother (2013) 62:897–908 901
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figure 1) was associated with a slight but significant
expansion of the CD4? T cell compartment (Fig. 2c) and
caused a robust increase in the number of circulating
CD4?CD25hiFoxp3? Tregs at B6 (i.e., at day 7 after the
last IL-2 administration) (% of Tregs mean ± SEM: B0
(1.7 ± 0.3), B6 (6.3 ± 0.8); p = 0.0005) (Fig. 2a). The
representative time-course analysis results, which are
available in Online figure 2, indicate that an increase in the
CD4?CD25hiFoxp3? Treg population occurred at day 7
after IL-2 administration (B6); however, this increase was
transitory and was no longer detectable after 15 days (B7).
No significant variations in the Treg and CD4 frequencies
were detected in the patients who were enrolled in the
control arm (Fig. 2b, d). In Tregs, stable FOXP3 expres-
sion is ensured by the demethylation of a conserved region
of the FOXP3 intron 1 [27]. Therefore, methylation-spe-
cific quantitative PCR assays (MS-qPCR) can be used as an
alternative method to detect Tregs. The down-modulation
of the Treg frequency at days 4–7 after CTX administration
and the boost of Tregs at B6 (day 112), induced by IL-2,
were confirmed by this alternative MS-qPCR assay [28,
supplementary data].
IL-2-expanded circulating Tregs exerted suppressive
activity
The ex vivo functional status of circulating CD4?CD25hi-
Foxp3? Tregs was assessed by analyzing TGF-b1 pro-
duction upon TCR stimulation. As reported in Fig. 3a, a
significant boost in the frequency of TGF-b1-producing
Tregs was detected in the PBMCs of the vaccinated
patients collected 4–7 days after IL-2 administration (B6)
[TGF-b1-producing Tregs mean ± SEM: B6 (1.8 ± 0.7)
vs. B4 (0.3 ± 0.1), p = 0.0026]. No significant variation in
the number of TGF-b1-producing Tregs was instead
observed in the PBMCs of the patients who were enrolled
in the control arm (Fig. 3b). Then, we assessed whether the
Tregs in the PBMCs after IL-2 administration could inhibit
the proliferation of conventional CD4?CD25- T cells.
In vitro suppression assays were performed using respon-
der CD4?CD25- T cells that were isolated from autolo-
gous, pre-vaccine PBMCs (B0, week-1). Figure 3c shows
that the Tregs that were isolated 4–7 days after IL-2
administration (B6, week 16) were endowed with the
expected, ratio-dependent inhibitory activity. The extent of
the suppression that was exerted by post-IL-2 Tregs was
similar to that of the pre-treatment Tregs isolated from
PBMCs at B0 in the same patient (Fig. 3d).
An increase in the number of Tregs by IL-2 did
not limit the vaccine-induced immunity in melanoma
patients
The immunological monitoring of the patients who were
enrolled in either the vaccine arm or the control arm of the
study was performed using HLA-A*0201/peptide multimer
(HLA-multimer) staining and IFN-c ELISpot assays. The
robust increase in the Treg frequency at B6, week 16, did
not limit the vaccine-induced expansion of peptide-specific
CD8? T cells. As reported for two representative patients
Fig. 2 CTX- and IL-2-induced
Treg modulation. Patient
PBMCs were collected at
different time points during the
vaccination (a, c) and
observation (b, d) periods (see
the Online figure 1). The
PBMCs were stained with
anti-CD4, anti-CD25, and
anti-Foxp3 mAbs and were
analyzed by FACS. The graphs
show the CD4?CD25hiFoxp3?
Treg frequency (Tregs) in the
gated CD4? T subset (a, b) and
the frequency of CD4? cells in
the gated lymphocytes
(c, d) (the p values were
calculated using Wilcoxon
statistical tests)
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in Fig. 4a, the pentamer-specific T cells, which were
detectable after the 2nd and third vaccinations (B4 and B5),
were either maintained or further boosted at B6 after IL-2
administration. More importantly, the antigen-specific
CD8? T cells, which were detected at B6 with the con-
comitant expansion of Tregs, were functionally active and
actively released IFN-c upon antigenic stimulation
(Fig. 4b). Ex vivo IFN-c ELISpot assays indicated that the
frequencies of the CD8? T cells that responded to the
tumor-associated peptides, which composed the vaccine,
were increased after the 2nd vaccination (B2–B5, Fig. 4b).
The frequencies of these specific T cells were maintained
or further increased after IL-2 administration (B6, Fig. 4b)
as confirmed in a larger set of vaccinated patients (Fig. 4c).
Further immunological characterization of the vaccine-
induced T cell response has been reported elsewhere [26].
Fig. 3 The Tregs expanded by IL-2 exerted suppressive activity.
Patient PBMCs were collected at different time points, activated
ex vivo with anti-CD3/CD28 beads and stained for Treg markers and
TGF-b1. The graphs show the percentages of TGF-b1? Tregs among
the CD4? lymphocytes in the vaccinated patients (a) and in the
control patients (b) at different time points (the p value was calculated
using Wilcoxon statistical tests). c, d CFSE-labeled CD41CD252 T
cells were stimulated with anti-CD3/CD28 beads and assessed for
their proliferative capacity after 72 h in the presence of a decreasing
ratio of autologous Tregs (shaded histograms). The unshaded
histograms represent unlabeled CD4?CD25- T cells. CD41CD252
responder T cells were isolated from PBMCs at week -1 (B0 CD25-).
Tregs were purified from the PBMCs of the same patient at week -1
(B0 Tregs) or after IL-2 administration (B6 Tregs). Proliferation was
reported as the mean percentage of two technical replicates. The
results from one (Pt# 4) out of 3 patients who were studied are shown
Cancer Immunol Immunother (2013) 62:897–908 903
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CD4? T cells boosted by IL-2 included T helper type-I-
like Foxp3? Tregs and conventional activated T cells
The significant boost in antigen-specific CD8? T cells
observed in the peripheral blood concomitantly with the
IL-2-mediated increase in Tregs prompted us to further
investigate the functional features of the circulating Tregs
in the vaccinated patients and better understand the nature
of the CD4? T cells that were boosted by the low-dose IL-2
treatment.
In line with the knowledge that activated CD4?CD25hi-
Foxp3? Tregs are highly proliferative, we observed that a
relatively high percentage of Tregs in both pre- and post-IL-2
PBMC expressed Ki67 (Fig. 5a, left panel). In addition, we
observed that activated Tregs that were derived from IL-2-
treated PBMCs expressed increased levels of T-bet and
accumulated significant amounts of intracellular IFN-c
(Fig. 5a, central and right panels). The presence of IFN-c-
positive Tregs was confirmed after we extended the analysis
to all of the vaccinated patients (Fig. 5b, left panel). No IFN-c-
positive Tregs were found in the control patients (Fig. 5b,
right panel). Using a gating strategy that selectively consid-
ered CD4? T cells with a high expression of CD25 and Foxp3,
we excluded conventional activated T cells that expressed
CD25 and Foxp3 at intermediate levels [16]. Thus, although
INF-c expression and T-bet positivity are also traits of con-
ventional Th1 cells, our data suggest that a fraction of Tregs,
due to their functional plasticity, expressed a T helper type-I-
like phenotype in the vaccinated patients. In human autoim-
mune diseases [29, 30], T helper type-I-like Foxp3? Tregs
depend on the availability of the Th1-inducing cytokine IL-12.
As shown in Fig. 5c, IL-12p70 was detected in the post-vac-
cine sera, whereas this cytokine was not observed in the pre-
vaccine sera or in the sera from patients in the control arm or
from healthy donors [IL-12p70 pg/ml mean ± SEM: VAX-
pre B0 (0.2 ± 0.2), VAX-post B6 (13.7 ± 6.7); p = 0.0313].
According to Miyara [16], conventional activated CD4?
T cells are defined as CD4?CD25intFoxp3intCD45RAneg
cells and they can be discriminated from Tregs. This gating
strategy (Fig. 6a, gated as Fr.a) allowed us to further
Fig. 4 The CD8? T cell response to the vaccine peptides was not
affected by Treg expansion. a The PBMCs from the vaccinated
patients were analyzed ex vivo using HLA-A*0201/peptide multimer
staining at different time points during the vaccination period. The
percentage of multimer-positive cells were calculated in the CD8?
gate (points and connection lines) and reported with the percentage of
CD4?CD25hiFoxp3? Tregs (white bars) in the PBMCs from two
representative patients (Pt# 3 and Pt# 5). b The CD8? T cell response
to the vaccine peptides was measured by IFN-c-ELISpot assay (points
and connection lines), and the percentage of CD4?CD25hiFoxp3?
Tregs were measured by FACS analysis (white bars). Two represen-
tative patients are shown (Pt# 1 and Pt# 3). c The CD8? T cells that
released IFN-c in response to the peptides are shown in the graphs at
four time points during vaccination: pre-vaccination (B0), after the
second vaccination (B4), before IL-2 administration (B5), and after
IL-2 administration (B6) (n = 16; the p value was calculated using
Wilcoxon statistical tests. Only the significant p values are shown)
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characterize the nature of the CD4? T cells that were
boosted by low-dose IL-2. As presented in Fig. 6, IL-2
administration led to the consistent enhancement of con-
ventional activated CD4? T cells in the PBMCs of the
treated patients (B4 vs. B6, p = 0.0313, Fig. 6b). Taken
together, these data confirmed that low-dose IL-2 mediated
the expansion of activated conventional CD4? T cells
concomitantly with Treg functional plasticity toward a
Th1-like phenotype.
Discussion
The effect of metronomic doses of CTX on circulating
Tregs is well documented in advanced cancer patients
[7, 8]; however, less and ambiguous data are available on
the modulating capacity of this drug when administered at a
low-dose in patients with a low tumor burden [12–14]. In
addition, data from murine models have indicated that gene
and protein expressions are modulated early and transiently
by CTX with a maximum effect that is detectable after 24 h
of CTX administration; however, no conclusive data have
been produced on the kinetics of CTX effects in humans
[31]. In our study, we evaluated the effect of low-dose CTX
administration on Tregs in the context of a HLA-A*0201-
modified tumor peptide vaccine in stage II–III melanoma
patients. Our data indicate that CTX slightly decreased the
number of circulating Tregs in the vaccinated patients. This
reduction, that occurred early after the first CTX injection,
was transient despite the subsequent administration of
additional CTX doses. In contrast to previous reports, our
study included melanoma patients in the early disease
stages (stage IIB/C–III) with a baseline frequency of cir-
culating Tregs that was slightly above the values observed
in healthy donors and significantly lower than those detec-
ted in stage IV melanoma patients (Online figure 3).
In this study, the status of the Tregs in the LNs that were
surgically removed from patients with lymph nodal tumor
involvement was also assessed. Our data strongly suggest
that CTX may be more effective at limiting tumor-induced
Tregs at the tumor site rather than the circulating Treg
pool. In fact, the frequency of activated Tregs was lower in
the LNs of the patients who were treated with CTX com-
pared with that in the LN of control patients. This
Fig. 5 The vaccine-induced
Tregs with a Th1-like
phenotype. a The expression of
Ki67, T-bet, and IFN-c before
IL-2 administration (B4) and
after IL-2 administration (B6)
was evaluated in the Tregs of
three vaccinated patients.
b Patient PBMCs were activated
ex vivo with anti-CD3/CD28
beads and were stained for Treg
markers and IFN-c as described
in the section Materials and
methods. The percentage of
IFN-c? Tregs among the CD4?
T cells in the PBMCs of the
vaccinated patients (n = 16, left
panel) and the control patients
(n = 15, right panel) are shown
(The p value was calculated
using Wilcoxon statistical tests).
c The histograms indicate the
release of IL-12p70 (pg/ml) in
the sera of the healthy donors
(HD, n = 10), control patients
(CRL, n = 6) and vaccinated
patients (VAX, n = 8) pre- (B0)
and post-vaccination (B6). [The
p value was calculated using
Wilcoxon statistical tests; the
error bars represent the standard
error of the mean (SEM)]
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observation is in agreement with the data that were
obtained in pre-clinical models, which demonstrated that
CTX selectively depletes the Treg cycling population [32]
and Tregs with an effector/memory phenotype and tumor-
homing activity [33]. In parallel with this Treg reduction, a
low level of immunosuppressive cytokines, such as IL-10,
TGF-b1, IL-6, and VEGF, was detected in the LNs of the
treated patients compared with the control patients. The
LNs were dissected and analyzed in the vaccinated
patients after one dose of CTX and after two vaccine
injections; therefore, the less immunosuppressive milieu
could have resulted from the synergistic interaction
between CTX and the stimulating activity of the peptide-
based immunization. Because study arms including CTX
treatment alone or peptide vaccine treatment alone were
not incorporated into the trial design, this hypothesis can-
not be further tested. Similarly, the effect of the modulatory
activities of CTX and IL-2 on circulating Tregs can be
indirectly evaluated by the accurate time-course analysis of
the patients who were enrolled in the vaccination arm
compared with the patients who only received surgical
treatment.
In our study, low-dose CTX demonstrated a limited
capacity to modulate circulating Tregs; however, low-dose
IL-2 produced a remarkable boost of CD4?CD25hiFoxp3?
Tregs in PBMCs. This enhancement was evident at day 7
after IL-2 administration but was transient and no longer
detectable after day 15 (Online figure 2). IL-2-boosted
Tregs were immunosuppressive as demonstrated in the
in vitro suppressive assay performed on representative
cases and by their capacity to produce the immunosup-
pressive cytokine TGF-b1. TGF-b1 is a key cytokine in
Treg-mediated suppression [34–37], and variations in the
frequency of TGF-b1-producing Tregs may impact clinical
outcomes [38]. Therefore, our data suggest that low-dose
IL-2 directly affects Treg homeostasis by inducing the
expansion of immunosuppressive Tregs in a similar manner
as high-dose IL-2 [20].
Tumor-specific Tregs actively suppress the proliferation
of CD4?CD25- and CD8? effector T cells, thereby lim-
iting the immune response against cancer and contributing
to tumor growth [39, 40]. A recent study found that levels
of peripheral Tregs were negatively correlated with the
clinical response to adoptive immunotherapy in melanoma
patients, and Treg reconstitution depended on the number
of IL-2 doses that were administered [41].
In this study, accurate time-course analysis of PBMCs of
vaccinated patients indicated that the expansion or the
functional activation of antigen-specific CD8? T cells
induced by vaccination was maintained or further increased
in PBMCs collected after IL-2 administration despite the
concomitant boost in Tregs.
Therefore, we investigated the CD4? T cell compart-
ment that was amplified by IL-2 administration in the
vaccinated patients. Interestingly, we found that a subset of
Tregs in IL-2-treated PBMCs revealed a T helper type
1-like phenotype at the end of the vaccination cycle. This
cell subset was recently described in the context of human
autoimmune diseases [29, 30] and is IL-12p70 dependent.
This cytokine was detectable in the serum of patients post-
treatment but not in pre-vaccine sera or in the sera from
patients in the control arm. These results confirm the
intrinsic plasticity of Tregs and suggest that the pro-
inflammatory environment in vaccinated patients can
reprogram Tregs into Th-1-like T cells, thus promoting an
anti-tumor CD8 response. To our knowledge, these results
are the first evidence of Treg functional plasticity occurring
in peptide-vaccinated cancer patients. However, the exis-
tence of an active interplay between vaccination and the
Treg compartment has been previously documented by
Romero and colleagues who reported that peptide-based
vaccine was able to reduce the frequency of circulating
peptide-specific Tregs in melanoma patients [42].
T helper type 1-like Tregs and conventional activated T
cells were susceptible to IL-2-mediated expansion. There-
fore, as demonstrated in different settings [43], the balance
between the different functional T cell subsets that are
Fig. 6 IL-2 administration increased the conventional CD4? T cell
frequency. a According to Miyara et al. [16], the conventional
activated CD4? T cell subset is defined as CD45RAnegCD25low (Fr.
a), and this subset was detected in the PBMCs before (B4) and after
IL-2 administration (B6). The dot plots of a representative patient
(Pt# 33) show the FACS gating strategy. b The frequency of
conventional CD4? T cells (Fr. a) in patient PBMCs before (B4) and
after IL-2 administration (B6) is shown (n = 6; the p value was
calculated using Wilcoxon statistical tests)
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regulated by IL-2 is a crucial factor that influences the
immunological outcomes of vaccinated patients.
Our data emphasize the importance of the functional
monitoring of Tregs and suggest that low-dose IL-2
administration in patients receiving peptide-based vaccine,
although associated with a boost in circulating Tregs in
PBMCs collected after IL-2 administration, was not par-
alleled by an impairment in the expansion and the effector
functions of antigen-specific CD8? T cells induced by
vaccination. In contrast, on the basis of our data, the use of
CTX requires further study to define the optimal adminis-
tration schedules and the types of patients who would
benefit from this drug.
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